Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs T Rowe Price Group Inc (TROW) Price & Performance

Humana IncTrade
T Rowe Price Group IncTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs T Rowe Price Group Inc — how do they compare? Humana Inc trades at $442 (market cap $47.61B), while T Rowe Price Group Inc trades at $104.25 (market cap $22.20B). The key difference: Humana Inc is far larger — about 2.1× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (5%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and T Rowe Price Group Inc for 115 Days on average.

HUMTROW
Market Cap
$47.61B$22.20B
Volume
1,827,3321,738,431
Sector
HealthFinancials
52-Week High
$409.85$121.68
52-Week Low
$163.67$86.19
Typical Hold Time
53 Days115 Days
Enterprise Value
$54.97B$19.39B
Dividend Yield
0.89%5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.

Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.

T Rowe Price Group Inc

T. Rowe Price (TROW) trades at $104.23, up 0.61% with bearish technical signals but strong fundamentals including a 29.26% net margin and $2.09B net income. The stock shows consistent earnings beats and dividend growth, supported by $1.90 trillion in assets under management as of August 2026. Recent news highlights dividend sustainability and ETF expansion through acquisitions.

Outlook remains positive with a $112 consensus price target offering 7.5% upside, though technical weakness and market volatility pose near-term risks. The company's 40-year dividend growth history and expanding product portfolio provide stability, while net outflows and competitive pressures require monitoring for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →

About T Rowe Price Group Inc

T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.

Read more on TROW →